ACIP Support Of FDA-Approved Prevnar 13 Creates Prospect For Larger Market

In a long-awaited move, the FDA approved on Feb. 23 Pfizer's Prevnar 13 vaccine for pneumococcal disease in children 5 years of age and younger, a crucial step in the drug maker's ability to build out the vaccine franchise that was central to its acquisition last year of Wyeth